Monograph
J01DC02 - Cefuroxime |
Propably not porphyrinogenic |
PNP |
Rationale
Conflicting references Not metabolised. No data pointing to CYP-interaction. Some clinical experience of non-porphyrinogenicity.
Chemical description
Parenteral cephalosporin antibiotic used (up to 1.5 g x 3) eg in bacterial pneumonia, upper urinary tract infection and several other cono dataitions. Not significantly metabolized. Mainly excreted in unchanged form in urine. No data pointing to CYP affinity. South African list: use with caution . French list: avoid. Australian list: unsafe, conflicting evidence. Martindale: Cefuroxime is considered unsafe in patiets with porphyria although there is conflicting experimental evidence of porphyrinogenicity. Drug Consult: safe Andersson: Used a few times witout side effects.
IPNet drug reports
Uneventful use reported in 10 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia
